Skip to main content
    T

    Tactile Systems Technology Inc (TCMD)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $26.37
    -0.44 (-1.64%)

    Market Cap: $600.58M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Tactile Systems Technology Inc (TCMD) Earnings: Report Dates and Results

    Updated Nov 2, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Tactile Systems Technology (TCMD) is expected to report earnings on Feb 15, 2027. In the quarter ended Sep 30, 2026, Tactile Systems Technology reported EPS of $0.31, above the $0.30 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    72%(28/39)
    Avg Surprise
    +32.13%
    Streak
    5 Q

    Upcoming Estimates

    Reports Feb 15, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.57
    Range$0.49 - $0.66
    6 analysts
    Revenue Consensus
    $111.84M
    Range$107.02M - $115.71M
    6 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.09
    Range-$0.01 - $0.18
    2 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.14-37.0%
    60d ago$0.14-37.0%
    30d ago$0.14-37.0%
    7d ago$0.14-37.0%
    Current$0.09
    Revenue Consensus
    $81.37M
    Range$80.60M - $82.00M
    4 analysts

    Next Report

    TCMD has an expected report date of Feb 15, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 23.9% above the $0.46 reported for the quarter ended Dec 31, 2025.

    TCMD Earnings Call

    The latest TCMD earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, TCMD beat 28, missed 10 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $91.86M, up 7.1% from $85.75M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.31$0.30N/A+3.33%Beat-13.9%20 up, 2 downNov 2, 2026$91.86M
    Jun 30, 2026$0.34$0.14N/A+142.86%Beat+142.9%21 up, 0 downAug 10, 2026$85.70M
    Mar 31, 2026$0.00-$0.04-$0.08 - $0.01+106.00%BeatN/A22 up, 0 downMay 4, 2026$75.27M
    Dec 31, 2025$0.46$0.45$0.44 - $0.45+3.37%Beat+15.9%22 up, 0 downFeb 17, 2026$103.59M
    Sep 30, 2025$0.36$0.21$0.20 - $0.21+71.43%Beat+44.0%22 up, 0 downNov 3, 2025$85.75M
    Jun 30, 2025$0.14$0.14$0.11 - $0.180.00%In line-30.0%20 up, 2 downAug 4, 2025$78.91M
    Mar 31, 2025-$0.11-$0.06-$0.08 - -$0.05-83.33%MissN/A20 up, 2 downMay 5, 2025$61.27M
    Dec 31, 2024$0.40$0.28$0.25 - $0.31+41.79%Beat+13.4%20 up, 2 downFeb 18, 2025$85.58M
    Sep 30, 2024$0.25$0.17$0.16 - $0.19+47.06%Beat-70.6%50 up, 0 downNov 4, 2024$73.09M
    Jun 30, 2024$0.20$0.14$0.06 - $0.16+42.86%Beat+400.0%40 up, 0 downAug 5, 2024$73.22M
    Mar 31, 2024-$0.05-$0.01N/A-400.00%MissN/A30 up, 0 downMay 6, 2024$61.09M
    Dec 31, 2023$0.35$0.19$0.14 - $0.32+84.21%Beat+52.2%30 up, 0 downFeb 20, 2024$77.65M
    Sep 30, 2023$0.85$0.02N/AN/AN/A+844.4%30 up, 0 downNov 6, 2023$69.59M
    Jun 30, 2023$0.04-$0.02-$0.08 - $0.00+300.00%BeatN/A30 up, 0 downAug 7, 2023$68.34M
    Mar 31, 2023-$0.03-$0.20-$0.40 - -$0.13+85.00%BeatN/A40 up, 0 downMay 8, 2023$58.85M
    Dec 31, 2022$0.23$0.14$0.13 - $0.15+64.29%BeatN/A30 up, 0 downFeb 21, 2023$73.90M
    Sep 30, 2022$0.09-$0.05-$0.12 - -$0.05+280.00%BeatN/A40 up, 0 downNov 7, 2022$65.26M
    Jun 30, 2022-$0.15-$0.07-$0.20 - -$0.06-114.29%Miss-314.3%30 up, 0 downAug 1, 2022$59.65M
    Mar 31, 2022-$0.42-$0.20-$0.54 - -$0.16-110.00%MissN/A40 up, 0 downMay 2, 2022$47.98M
    Dec 31, 2021-$0.28$0.05-$0.14 - $0.28-660.00%Miss-150.9%51 up, 0 downFeb 22, 2022$61.73M
    Sep 30, 2021-$0.17$0.12$0.07 - $0.17-241.67%Miss-241.7%5N/ANov 8, 2021$52.50M
    Jun 30, 2021$0.07$0.02-$0.05 - $0.10+250.00%BeatN/A5N/AAug 2, 2021$51.06M
    Mar 31, 2021-$0.12-$0.19-$0.40 - -$0.06+36.84%BeatN/A5N/AMay 3, 2021$42.77M
    Dec 31, 2020$0.55$0.24$0.16 - $0.30+129.17%Beat+111.5%6N/AFeb 23, 2021$59.24M
    Sep 30, 2020$0.12-$0.06-$0.25 - $0.13+300.00%Beat0.0%6N/ANov 2, 2020$49.09M
    Jun 30, 2020-$0.72-$0.23-$0.40 - -$0.08-213.04%Miss-614.3%7N/AAug 3, 2020$35.12M
    Mar 31, 2020-$0.05-$0.02-$0.15 - $0.11-150.00%Miss-162.5%7N/AMay 4, 2020$43.67M
    Dec 31, 2019$0.26$0.27$0.19 - $0.32-3.70%Miss+4.0%7N/AFeb 26, 2020$11.86M
    Sep 30, 2019$0.12$0.11$0.06 - $0.17+9.09%Beat+33.3%7N/ANov 4, 2019$49.61M
    Jun 30, 2019$0.14$0.08$0.01 - $0.09+75.00%Beat+100.0%8N/AAug 5, 2019$90.40M
    Mar 31, 2019$0.08-$0.06-$0.10 - -$0.01+233.33%BeatN/A6N/AMay 6, 2019$37.62M
    Dec 31, 2018$0.25$0.14$0.05 - $0.25+78.57%Beat+108.3%7N/AFeb 28, 2019$46.45M
    Sep 30, 2018$0.09$0.08$0.00 - $0.11+12.50%Beat+28.6%7N/ANov 5, 2018$36.32M
    Jun 30, 2018$0.07$0.03$0.00 - $0.14+133.33%Beat+75.0%7N/AAug 6, 2018$34.13M
    Mar 31, 2018$0.00-$0.14-$0.20 - -$0.07+98.00%BeatN/A7N/AMay 7, 2018$26.85M
    Dec 31, 2017$0.12$0.13$0.10 - $0.16-7.69%Miss-7.7%7N/AFeb 26, 2018$34.89M
    Sep 30, 2017$0.07$0.05$0.02 - $0.07+40.00%Beat+600.0%6N/ANov 7, 2017$28.28M
    Jun 30, 2017$0.04$0.01-$0.04 - $0.02+300.00%Beat-42.9%4N/AAug 7, 2017$26.26M
    Mar 31, 2017-$0.09-$0.16N/A+43.75%BeatN/AN/AN/AMay 8, 2017$19.85M
    Dec 31, 2016$0.13$0.04N/A+225.00%BeatN/AN/AN/AFeb 27, 2017$28.48M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.85, up 6.6% from the year before. It was $0.21 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.85+6.6%
    Dec 31, 2024$0.80-34.1%
    Dec 31, 2023$1.21N/A
    Dec 31, 2022-$0.25N/A
    Dec 31, 2021-$0.50N/A
    Dec 31, 2020-$0.10-116.7%
    Dec 31, 2019$0.60+47.3%
    Dec 31, 2018$0.41+190.9%
    Dec 31, 2017$0.14-33.3%
    Dec 31, 2016$0.21N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,300 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,2858
    2026Q2Jun 30, 20266,9088
    2026Q1Mar 31, 20265,6608
    2025Q4Dec 31, 20256,5918
    2025Q3Sep 30, 20257,1569
    2025Q2Jun 30, 20256,8768
    2025Q1Mar 31, 20257,7598
    2024Q4Dec 31, 20248,2859

    2026Q3 Earnings Call

    Opening remarks

    Sam Bentzinger Investor Relations Good afternoon, and thank you for joining today's call. With me from Tactile Medical's management team are Sheri Dodd, Chief Executive Officer, and Elaine Birkemeyer, Chief Financial Officer. Before we begin, I'd like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties. This could cause actual results to differ materially from those indicated, including those identified in the Risk Factors section of our annual report on Form 10-K as well as our most recent 10-Q filing to be filed with the Securities and Exchange Commission. Such factors may be updated from time to time in our filings with the SEC, which are available on our website. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events, or otherwise. This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles, or GAAP. We generally refer to these as non-GAAP financial measures. Reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the Investor Relations portion of our website. With that, I'll now turn the call over to Sheri.

    Sheri Dodd CEO Thanks, Sam. Good afternoon, everyone, and welcome to our third quarter 2026 earnings call. Here with me is Elaine Birkemeyer, our Chief Financial Officer. We delivered total revenue of $91.9 million in Q3, led by 13% year-over-year growth in lymphedema, marking our fifth consecutive quarter of above-market double-digit growth. This consistency demonstrates the durability of our leadership position and the substantial runway created by a market that remains significantly underpenetrated. Airway clearance revenue was $10 million, down year-over-year as anticipated due to the one-time DME inventory transition associated with the launch of our next-generation AffloVest system. The same DME customers we highlighted in Q2 continued to work through temporary excess inventory during Q3. There were no material changes in the underlying dynamics of the business, and we continue to expect airway clearance revenue to improve sequentially in the fourth quarter. Across the portfolio, we continue to balance strong growth in our core lymphedema business with disciplined execution. Gross margin expanded 90 basis points year-over-year in Q3 to 76.7%, contributing to adjusted EBITDA of $14.3 million. This marks the 12th consecutive quarter of year-over-year gross margin expansion. Importantly, we have achieved this sustained improvement while continuing to invest in our product offerings to deliver greater value to patients and providers.

    Frequently Asked Questions About TCMD

    When is Tactile Systems Technology's next earnings date?

    Tactile Systems Technology's next earnings report is expected for Feb 15, 2027.

    Did TCMD beat earnings estimates last quarter?

    Yes. Tactile Systems Technology reported EPS of $0.31 for the quarter ended Sep 30, 2026, above the $0.30 estimate, a 3.33% surprise.

    What EPS do analysts expect from TCMD next quarter?

    The consensus EPS estimate for Tactile Systems Technology for the quarter ending Dec 31, 2026 is $0.57 from 6 analysts, with estimates from $0.49 to $0.66.

    How often does TCMD beat earnings estimates?

    Tactile Systems Technology beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +35.68%.